An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.
read more
Co-Author
Rahul Gotadki
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed scientific journals, biotechnology publications, and authoritative life sciences organizations. Key sources included the US Food & Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), European Medicines Agency (EMA) Committee for Advanced Therapies (CAT), International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), National Institutes of Health (NIH) National Center for Biotechnology Information (NCBI/PubMed), NIH National Human Genome Research Institute (NHGRI), National Institute of Standards and Technology (NIST) Genome Editing and Synthetic Biology Consortium, World Health Organization (WHO) International Nonproprietary Names (INN) Programme, ClinicalTrials.gov registry, European Directorate for the Quality of Medicines & HealthCare (EDQM), US Patent and Trademark Office (USPTO) and European Patent Office (EPO) patent databases, American Chemical Society (ACS) Chemical Abstracts Service, Biotechnology Innovation Organization (BIO) industry reports, International Society for Pharmaceutical Engineering (ISPE) good manufacturing practice guidelines, Pharmaceutical Research and Manufacturers of America (PhRMA) pipeline reports, and national health statistics from the CDC National Center for Health Statistics regarding cancer, genetic diseases, and infectious disease prevalence. These sources were used to collect therapeutic oligonucleotide pipeline data (antisense oligonucleotides, siRNA, miRNA, gene therapy raw materials), regulatory approval tracking for oligonucleotide therapeutics, genomic research funding metrics, synthesis technology patent landscapes, and market landscape analysis for synthetic DNA/RNA service providers, reagent manufacturers, and synthesis equipment vendors.
Primary Research
Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources comprised CEOs, General Managers of Oligonucleotide Business Units, Chief Scientific Officers (CSOs), Heads of Synthetic Biology, VPs of Manufacturing Sciences, regulatory affairs directors, and commercial leads from oligonucleotide synthesis companies, DNA/RNA contract manufacturers (CDMOs), sequencing technology providers, and synthetic biology platforms. Demand-side sources included Chief Scientific Officers of pharmaceutical and biotechnology companies, Heads of Oligonucleotide Therapeutics Discovery, Directors of Genomics at academic research institutions, principal investigators at genome editing research centers, procurement managers at molecular diagnostic laboratories, and supply chain directors at cell and gene therapy companies. Primary research has confirmed the adoption patterns of custom synthesis versus catalog products, validated market segmentation across therapeutic-grade vs. research-grade oligonucleotides, and gathered insights on manufacturing scale-up challenges, regulatory quality requirements (cGMP vs. research-only), pricing dynamics for phosphoramidite chemistries, and vendor consolidation trends.
Primary Respondent Breakdown:
By Designation: C-level Executives (28%), VP/Director Level (32%), Managers/Scientists/Others (40%)
By Region: North America (32%), Europe (30%), Asia-Pacific (25%), Rest of World (13%)
Market Size Estimation
Global market valuation was derived through revenue mapping and synthesis volume analysis. The methodology included:
Identification of 50+ key manufacturers and service providers across North America, Europe, Asia-Pacific, and emerging biotech hubs, including pure-play oligonucleotide synthesis companies, diversified life science tools providers, and oligonucleotide therapeutics developers with captive manufacturing
Product mapping across DNA oligonucleotides, RNA oligonucleotides (siRNA, miRNA, mRNA precursors), modified nucleotide chemistries, synthesis reagents (phosphoramidites, solid supports, fluorous reagents), and synthesis equipment (synthesizers, purification systems)
Analysis of reported and modeled annual revenues specific to oligonucleotide synthesis portfolios, including therapeutic API manufacturing, diagnostic probe synthesis, and research reagent segments
Coverage of manufacturers and service providers representing 75-80% of global market share in 2024
Extrapolation using bottom-up (synthesis volume × average selling price by application: research-grade vs. therapeutic-grade vs. diagnostic-grade, stratified by oligo length and modification complexity) and top-down (manufacturer revenue validation against public filings and modeled private company revenues) approaches to derive segment-specific valuations for custom oligonucleotides, predesigned/catalog oligonucleotides, synthesis reagents, and instrumentation
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah MalgeriCo-Founder
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph AguayoSales Operations & Pricing Manager
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkampAccount and Business Manager
“Thank you, this will be very helpful for OQS.”
La Terria DoddProgram Support Specialist
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan ChoiSenior Retail Manager
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile").
In general the report is well structured. Thanks very much for your efforts.”
Mark IrwinManagement Consultant
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob KooikerGroup Product Manager HVAC & Fire Protection GMA
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif MorogluStrategy & Business Development Director
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
Guilherme Gomes MartinsProduct Management Director